Immupharma Plc Stock Current Valuation
| IMM Stock | 1.47 0.08 5.16% |
Valuation analysis of ImmuPharma PLC helps investors to measure ImmuPharma PLC's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that ImmuPharma PLC's price fluctuation is very risky at this time. Calculation of the real value of ImmuPharma PLC is based on 3 months time horizon. Increasing ImmuPharma PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ImmuPharma stock is determined by what a typical buyer is willing to pay for full or partial control of ImmuPharma PLC. Since ImmuPharma PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImmuPharma Stock. However, ImmuPharma PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.47 | Real 1.34 | Hype 1.47 | Naive 1.44 |
The real value of ImmuPharma Stock, also known as its intrinsic value, is the underlying worth of ImmuPharma PLC Company, which is reflected in its stock price. It is based on ImmuPharma PLC's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ImmuPharma PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ImmuPharma PLC helps investors to forecast how ImmuPharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImmuPharma PLC more accurately as focusing exclusively on ImmuPharma PLC's fundamentals will not take into account other important factors: ImmuPharma PLC Company Current Valuation Analysis
ImmuPharma PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ImmuPharma PLC Current Valuation | 6.02 M |
Most of ImmuPharma PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuPharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ImmuPharma PLC has a Current Valuation of 6.02 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United Kingdom stocks is notably lower than that of the firm.
ImmuPharma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuPharma PLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuPharma PLC could also be used in its relative valuation, which is a method of valuing ImmuPharma PLC by comparing valuation metrics of similar companies.ImmuPharma PLC is currently under evaluation in current valuation category among its peers.
ImmuPharma Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 6.02 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Shares Owned By Insiders | 48.33 % | ||||
| Shares Owned By Institutions | 17.44 % | ||||
| Price To Book | 2.31 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | 118.35 K | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 6.76 M | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
| Working Capital | (321.92 K) | ||||
| Net Asset | 2.72 M |
About ImmuPharma PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuPharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuPharma PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuPharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.